Robert Wang, MD
Ophthalmology · Dallas, TXNPI 1568447175
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,745 of the $144,176 with a category attached, or 62.2%. It is spread thinly across 23 manufacturers, the largest accounting for just 19.2%. Reporting peaked in 2019 at $42,963 and has fallen 52.9% since, to $20,254 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $388.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$28K
- Eyepoint US, Inc.$24K
- Bausch & Lomb Americas Inc.$23K
- Genentech USA, Inc.$21K
- Mallinckrodt Hospital Products Inc.$19K
- ANI Pharmaceuticals, Inc.$11K
- plus $18K from 17 others
Across 12 payments — averaging $37,444 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$432K
- Eyepoint US, Inc.$18K
- AbbVie$150
What the payments were for
- Consulting fees$37,46526%
- Speaking & faculty fees$89,74562%
- Travel & lodging$3,1252%
- Food & beverage$13,6149%
- Education$2260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 30 | $27,750 |
| Eyepoint US, Inc. | 24 | $23,931 |
| Bausch & Lomb Americas Inc. | 33 | $23,414 |
| Genentech USA, Inc. | 38 | $21,028 |
| Mallinckrodt Hospital Products Inc. | 48 | $18,648 |
| ANI Pharmaceuticals, Inc. | 20 | $11,468 |
| AbbVie(2 entities) | 48 | $4,577 |
| Harrow Eye, LLC | 9 | $3,315 |
| Alimera Sciences, Inc. | 17 | $3,280 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $1,616 |
| Novartis | 14 | $1,351 |
| Regeneron Healthcare Solutions, Inc. | 29 | $929 |
| Genentech, Inc. | 4 | $920 |
| Apellis Pharmaceuticals, Inc. | 19 | $834 |
| Coherus Oncology, Inc. | 9 | $401 |
| Astellas Pharma Global Development | 1 | $218 |
| Astellas Pharma US Inc | 6 | $183 |
| Amgen(2 entities) | 8 | $148 |
| Sandoz | 3 | $74 |
| Vyera Pharmaceuticals, LLC | 2 | $33 |
| Biotissue Holdings Inc. | 1 | $26 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$144,176 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 148 | $1,072,547 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $246,527 |
| Actemra ActpenTocilizumab | 34 | $128,692 |
| Difluprednate | 195 | $18,995 |
| ProlensaBromfenac Sodium | 41 | $18,268 |
| LumiganBimatoprost | 45 | $18,064 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $8,943 |
| Prednisolone Acetate | 208 | $8,736 |
| Mycophenolate Mofetil | 49 | $7,921 |
| Alphagan PBrimonidine Tartrate | 29 | $7,618 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $5,204 |
| Bromfenac Sodium | 26 | $4,703 |
| MethotrexateMethotrexate Sodium | 103 | $3,014 |
| Brimonidine Tartrate | 79 | $2,754 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $4,577 | $34,625100 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,616 | $18,26841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Oluwatosin SmithDallas$1.5M
- Davinder GroverDallas$705K
- Ashkan AbbeyDallas$559K
- Karl CsakyDallas$426K
- Jeffrey WhitmanDallas$190K
- Arvind NeelakantanDallas$90K
- Michael SingerSan Antonio$1.8M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Christina WengHouston$676K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.